Univercells announced the commercial launch of its proprietary NevoLine bioproduction system for vaccines. The system was initially developed as part of a $12 million Grand Challenges grant awarded by .....
Right after releasing positive results for its novel affordable vaccine manufacturing technology, Belgium’s Univercells closed a €16 million ($18.8 million) series B backed by funds on three continents.
Orgenesis Inc. (OTCQB: ORGS) has signed a master service agreement with Servier for the development of a manufacturing platform for allogeneic cell therapies. Under the master service agreement, MaSTherCell is developing a CAR-T cell therapy manufacturing